Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy. Moreover, studies...

Full description

Saved in:
Bibliographic Details
Published iniLIVER Vol. 1; no. 4; pp. 225 - 234
Main Authors Yan, Jingxin, Deng, Manjun, Kong, Shunyu, Li, Ting, Lei, Zhenwu, Zhang, Lushun, Zhuang, Yutong, He, Xin, Wang, Huanwei, Fan, Haining, Guo, Yingxing
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.12.2022
Subjects
Clinical evidence
Hepatocellular carcinoma
Programmed cell death-ligand 1
Programmed death 1
Transarterial chemoembolization
Programmed death 1
TKI
OS
AE
Transarterial chemoembolization
TACE
Hepatocellular carcinoma
HCC
Clinical evidence
PFS
ICI
Programmed cell death-ligand 1
Online AccessGet full text

Cover

More Information
Summary:Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide. With the development of systemic therapies, several studies are currently underway, especially those related to the use of programmed death-1/programmed cell death-ligand 1 (PD-1/PD-L1) immunotherapy. Moreover, studies on transarterial chemoembolization (TACE) and PD-1/PD-L1 immunotherapy have demonstrated some interesting outcomes. This article reviewed the current clinical evidence on the combination of TACE and PD-1/PD-L1 immunotherapy. Overall, our review summarized that a favorable survival time could be achieved using this combination in most patients. However, complications such as hyperprogression should be taken seriously, and the underlying mechanisms need to be explored.
ISSN:2772-9478
DOI:10.1016/j.iliver.2022.10.001